Development of cardiovascular risk prediction equations from SELECT trial data for people with established CVD and overweight/obesity without T2DM, estimating acute coronary syndrome and stroke risk as inputs for health economic models evaluating semaglutide. Enables calibrated CVD risk projections specific to the SELECT-eligible population rather than general population equations. Provides SELECT-derived risk equations for health technology assessment models—enabling more accurate cost-effectiveness calculations for semaglutide in the secondary CVD prevention indication by using population-specific rather than generalized cardiovascular risk parameters.
Bøg, Martin; Bojesen, Anders Bo; Emerson, Scott; Ivkovic, Milana; Jenkins, Nia C; Lübker, Christopher; Mamdani, Muhammad; Padgett, Thomas; Van Gaal, Luc; Weeke, Peter E; Lincoff, A Michael